Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) and Vaxart (NASDAQ:VXRT – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.
Volatility & Risk
Iovance Biotherapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Iovance Biotherapeutics and Vaxart, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Iovance Biotherapeutics | 0 | 0 | 10 | 0 | 3.00 |
| Vaxart | 0 | 0 | 2 | 0 | 3.00 |
Earnings & Valuation
This table compares Iovance Biotherapeutics and Vaxart’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Iovance Biotherapeutics | $1.19 million | 2,429.11 | -$444.04 million | ($1.80) | -5.74 |
| Vaxart | $7.38 million | 23.80 | -$82.46 million | ($0.53) | -1.87 |
Vaxart has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Iovance Biotherapeutics and Vaxart’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Iovance Biotherapeutics | -23,615.70% | -71.45% | -55.17% |
| Vaxart | -920.00% | -121.06% | -79.98% |
Institutional and Insider Ownership
77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 18.1% of Vaxart shares are held by institutional investors. 10.4% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 3.0% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Vaxart beats Iovance Biotherapeutics on 7 of the 13 factors compared between the two stocks.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
